Biotricity

111 articles with Biotricity

• Biotricity, Inc. to Attend 34th Annual Roth Conference March 13th-15th

  3/4/2022

  Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced that it will attend the 34th Annual Roth Conference, being held on March 13-15, 2022 at The Ritz Carlton, Laguna Niguel in Dana Point, California.

• Biotricity Now Taking Pre-Orders for its Biotres Wireless Wearable Cardiac Monitoring Device

  2/23/2022

  Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced that it is now taking pre-orders for Biotres, the Company's three-lead device designed to continuously record electro-cardiogram data for early detection of cardiac arrhythmias.

• 

  BioSpace Investigates Challenges with Compensation Disparity in the Life Sciences

  2/10/2022

  72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.

• Biotricity to Report Third Quarter Fiscal 2022 Financial Results on February 14, 2022

  2/8/2022

  Biotricity, Inc. announced that it will release its financial results for the third quarter of fiscal 2022, ended December 31, 2021, on Monday, February 14, 2022.

• Biotricity Receives FDA 510(k) Clearance for its Biotres Cardiac Monitoring Device

  1/24/2022

  Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, reported it has received 510 clearance from the U.S. Food and Drug Administration for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.

• Biotricity Expands Distribution of New Bioheart Device on Amazon.com

  12/28/2021

  Biotricity Inc. today announced it has expanded the distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring technology used by physicians, on Amazon.com.

• Biotricity Completes $12 Million Non-Dilutive Debt Financing

  12/27/2021

  Biotricity Inc. today announced the successful completion of a $12 million non-convertible debt financing.

• Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter

  12/7/2021

  Biotricity, Inc. has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development.

• Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor

  11/10/2021

  Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians.

• Biotricity Releases Fiscal 2022 Second Quarter Financial Results

  11/4/2021

  Biotricity Inc. today announced financial results for its 2022 fiscal year's second quarter ended September 30, 2021.

• Biotricity to Report Second Quarter Fiscal 2022 Financial Results on November 4, 2021

  11/2/2021

  Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced that it will release its financial results for the second quarter ended September 30, 2021, on Thursday, November 4, 2021, after the close of the market.

• Biotricity to Discuss its Breakthrough Patient Monitoring Solutions at Virtual LD Micro Main Event XIV on Oct. 13th

  10/12/2021

  Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced that its Chief Executive Officer Waqaas Al Siddiq is scheduled to present in-person at the Virtual LD Micro Main Event XIV in-person on Wednesday, October 13, 2021 at 5:00 PM PT/ 8:00 PM ET.

• Remote Medical Diagnostic Company, Biotricity, to Ring the Nasdaq Stock Market Opening Bell on Thursday, October 7th

  10/6/2021

  Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced it will be ringing the Opening Bell on the Nasdaq Stock Market on Thursday, October 7, 2021 at 9:30am E.T.

• Biotricity to Discuss its 2022 Strategic Outlook and Product Pipeline, at Benzinga Healthcare Small Cap Conference on Sept. 30

  9/28/2021

  Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced that its Chief Executive Officer Waqaas Al Siddiq is scheduled to present at the virtual Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021 at 12:15 p.m. ET.

• Biotricity to Discuss Expansion of Remote Monitoring Medical Device Products at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd

  9/21/2021

  Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced that its Chief Executive Officer Dr. Waqaas Al-Siddiq is scheduled to present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 2:55 p.m. ET.

• Biotricity Unveils "Biokit" with 3 Personal Medical Devices to Expand into Cardiac Disease Management

  9/14/2021

  Biotricity Inc. today announced that it has developed a personal medical device kit, Biokit, a bundled home-use set comprised of a digital thermometer, a pulse oximeter, and a blood pressure cuff.

• Biotricity Announces Closing of Exercise of Underwriter's Option to Purchase Additional Common Stock

  9/13/2021

  Biotricity, Inc. today announced that the underwriter of its previously announced underwritten public offering which closed on August 30, 2021, has partially exercised its option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commission.

• Biotricity to Discuss Sales Expansion, Recent Financing, and Wearable Medical Device Portfolio Expansion at H.C. Wainwright Conference

  9/8/2021

  Biotricity, Inc. today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021.

• Biotricity Completes Nasdaq Listing

  8/30/2021

  Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced the closing of an underwritten public offering of 5,000,000 shares of common stock of the Company for total gross proceeds to the Company of approximately $15 million.

• Biotricity Prices $15 Million Underwritten Public Offering of Common Stock and Listing on the Nasdaq Capital Market

  8/26/2021

  Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, announced the pricing of an underwritten public offering of 5,000,000 shares of common stock of the Company, at a price of $3.00 per share for total gross proceeds to the Company of approximately $15 million.